Cargando…

SGLT2 inhibitors in patients with HFpEF: how old is too old?

[Image: see text]

Detalles Bibliográficos
Autor principal:	Tong, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354734/ https://www.ncbi.nlm.nih.gov/pubmed/35935281 http://dx.doi.org/10.20517/jca.2022.30

Ejemplares similares

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

LBODP062 SGLT2 Inhibition Ameliorates Cognitive And Physical Impairment In Patients With HFpEF And Diabetes
por: Mone, Pasquale, et al.
Publicado: (2022)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping
por: Houstis, Nicholas E.
Publicado: (2020)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
por: Zhu, Zhaowei, et al.
Publicado: (2021)

Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients
por: Nguyen, Quyen L., et al.
Publicado: (2019)

Electrophysiological findings in HFpEF patients presenting for AF ablation
por: Lee, J, et al.
Publicado: (2023)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

Trimming the Fat in HFpEF: Learning How to Target the Metabolic Disease Phenotype
por: Schilling, Joel D.
Publicado: (2020)

OR19-2 Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) with Low and High Dose of Triiodothyronine: an Animal Model of Metabolic Syndrome with HFpEF
por: Almeida-Coelho, João, et al.
Publicado: (2022)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
por: Arvidsson, Per M., et al.
Publicado: (2022)

New antidiabetic therapy and HFpEF: light at the end of tunnel?
por: Tadic, Marijana, et al.
Publicado: (2021)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
por: Barilli, Maria, et al.
Publicado: (2022)

Reply: Diet-Induced Obesity HFpEF Murine Models
por: Valero-Muñoz, Maria, et al.
Publicado: (2018)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
por: Cuijpers, Ilona, et al.
Publicado: (2020)

Cat-apulting Toward a Molecular Understanding of HFpEF
por: Robinson, Emma L., et al.
Publicado: (2021)

Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
por: Justo da Silva, Gustavo Jose, et al.
Publicado: (2021)

Can mechanical circulatory support be an effective treatment for HFpEF patients?
por: Gude, Einar, et al.
Publicado: (2021)

Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF
por: Zhang, Yuhua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ddeh6iknmk086i96ibeblk0no3